AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 115 filers reported holding AKERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,170,915 | -34.5% | 359,251 | -39.5% | 2.81% | -18.5% |
| Q2 2023 | $27,745,579 | +22.0% | 594,251 | 0.0% | 3.45% | +12.2% |
| Q1 2023 | $22,736,043 | -30.2% | 594,251 | 0.0% | 3.08% | -21.5% |
| Q4 2022 | $32,564,955 | -3.8% | 594,251 | -40.2% | 3.92% | +5.0% |
| Q3 2022 | $33,854,000 | +60.5% | 994,251 | -55.5% | 3.74% | +5.9% |
| Q2 2022 | $21,095,000 | -33.4% | 2,232,251 | 0.0% | 3.53% | -11.9% |
| Q1 2022 | $31,676,000 | -32.9% | 2,232,251 | 0.0% | 4.00% | -7.6% |
| Q4 2021 | $47,212,000 | – | 2,232,251 | – | 4.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |